Clinical trial
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in…
NCT00190697 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190697 |
|---|---|
| Title | A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment |
| Official title | Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Breast Cancer, Endometrial Cancer, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | arzoxifene |
| Enrollment | 70 |
| Start date | Jan 1, 2001 |
| Completion | Apr 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | May 25, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: